AN2 Therapeutics Advances Chagas Disease and Oncology Programs and Reports Third Quarter 2025 Results
I'm PortAI, I can summarize articles.
AN2 Therapeutics Inc. reported its third quarter 2025 financial results, highlighting progress in its clinical pipeline. The company is advancing a Phase 1 trial for oral AN2-502998 targeting Chagas disease and plans a Phase 2 study with DNDi. Additionally, its M. abscessus program is in an investigator-initiated trial. In oncology, AN2 aims to develop boron-based targets for solid tumors, with a collaboration with GSK for TB inhibitors and continued funding from the Gates Foundation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments